moderate - Surgical volumes, particularly elective procedures in ambulatory surgical centers, exhibit moderate sensitivity to economic conditions. During recessions, patients may defer elective orthopedic and cosmetic procedures due to cost concerns or insurance coverage changes. However, emergency and urgent surgical procedures (trauma, cancer-related) remain relatively stable. The shift toward outpatient surgical settings (where EXPAREL has strong penetration) provides some insulation from acute care hospital budget pressures.

Rising interest rates have moderate impact through two channels: (1) higher borrowing costs on the company's $200M+ debt load, increasing interest expense and pressuring path to profitability, and (2) valuation multiple compression for unprofitable growth companies as investors demand higher returns. Lower rates benefit by reducing financing costs and making the stock more attractive on a discounted cash flow basis given negative near-term earnings.

growth - The stock attracts growth investors focused on specialty pharmaceutical companies with differentiated products addressing large markets (post-surgical pain management). Despite current unprofitability, the 75.7% gross margin and 18.3% FCF yield appeal to investors betting on operating leverage as the company scales. However, negative earnings growth (-337%) and declining stock performance (-14% over 1 year) have likely shifted the investor base toward value-oriented buyers seeking turnaround potential at 1.4x sales and 8.5x EV/EBITDA.